Abstract 2187
Background
The number of Chinese cancer survivors is increasing due to the trend of an aging population and improved cancer survival. It is urgently required to estimate the health status of cancer survivors and provide scientific evidence for future health care reform. This study aimed to evaluate the general health status of cancer survivors older than 45 years in China.
Methods
We identified cancer survivors (n = 354) and participants without cancer (n = 16,664) in the China Health and Retirement Longitudinal Study (CHARLS). Physical and mental health information collected by questionnaire were compared between cancer survivors and cancer-free controls.
Results
The mean age of cancer survivors was 61.0 years. More cancer survivors were female (68.9% vs. 52.3%, P < 0.001) and lived in a rural region (43.8% vs. 38.4%, P = 0.039) than those without cancer. Cancer survivors and participants without cancer did not show significant differences in age, marital status, education or BMI. The health status of middle-aged and older cancer survivors are shown in the table. Cancer survivors had more concomitant chronic diseases than participants without cancer (2.75 vs. 2.00, P < 0.001). The current health condition reported by cancer survivors themselves was poorer than no cancer group (3.87 vs. 3.38, P < 0.001). The daily activity score was higher in the cancer group (3.53 vs. 2.39, P < 0.001), which indicated that cancer survivors had more difficulties in their daily life than other middle-aged and older participants. There was no statistically significant difference in cognitive function between these two groups even after adjustment (12.61 vs. 12.90, P = 0.612). Cancer survivors had more depressive symptoms than participants without cancer after adjustment (10.07 vs. 8.01, P = 0.003).Table: 1649P
Health status of middle-aged and older cancer survivors and participants without cancer from the CHARLS
Characteristic | Total (N = 17,018) | Cancer survivors (n = 354) | No cancer (n = 16,664) | P value | P value† |
---|---|---|---|---|---|
Number of concomitant chronic diseases, mean ± SD | 2.02 ± 1.70 | 2.75 ± 2.13 | 2.00 ± 1.69 | <0.001 | |
Self-reported health score (1-5), mean ± SD | 3.39 ± 0.38 | 3.87 ± 0.82 | 3.38 ± 0.87 | <0.001 | <0.001 |
Daily activity, mean ± SD | 2.41 ± 3.36 | 3.53 ± 3.85 | 2.39 ± 3.35 | <0.001 | <0.001 |
Cognitive function, mean ± SD | 12.89 ± 5.69 | 12.61 ± 5.60 | 12.90 ± 5.69 | 0.629 | 0.612 |
Depression, mean ± SD | 8.05 ± 6.41 | 10.07 ± 7.06 | 8.01 ± 6.39 | <0.001 | 0.003 |
Adjusted for age, sex, region, and number of concomitant chronic diseases.
Conclusions
The health status of middle-aged and older cancer survivors is poor in China. High-quality and cost-effective supportive care for these individuals is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No. 61435001) and CAMS Innovation Fund for Medical Sciences (No. 2016-I2M-1-001, No. 2017-I2M-4-003).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract